Genus suffers legal setback Stateside
Genus suffered a legal setback Stateside as a US judge handed down a series of verdicts against the animal genetics specialist.
FTSE 250
20,591.40
17:00 03/01/25
FTSE 350
4,534.15
16:54 03/01/25
FTSE All-Share
4,490.88
17:14 03/01/25
Genus
1,538.00p
16:49 03/01/25
Pharmaceuticals & Biotechnology
20,224.34
16:54 03/01/25
The US District Court for Wisconsin ruled that two of Genus rival ST´s patents were valid and had been infringed and that ABS, a unit of Genus, had materially broken its confidentiality obligations as set out in the 2012 semen sorting agreement between the two parties.
The rulings were linked to Genus´s ABS unit´s GSS technology for sexing bovine semen that does not subject the sperm cells to high pressures and forces.
UK-based Genus said it was still awaiting the judge´s decisión on a number of motions related to the provisions of the 2012 agreement and that it would update the market further when the rulings were made.
A verdict on the damages related to those matters would be considered by the jury later this week, Genus said in a statement.